SCHEMBL2340576

SCHEMBL2340576

CC(=O)Nc1ccc(OP(=O)(O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
TDP1 Q9NUW8 2/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
SMN1; SMN2 Q16637 5/20 0.53
HTT P42858 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA9 Q16790 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
ALDH1A1 P00352 6/20 0.52
MAPT P10636 3/20 0.52
CA12 O43570 1/20 0.52
BRD4 O60885 1/20 0.52
NR1I2 O75469 1/20 0.52
MB P02144 1/20 0.52
CYP1A1 P04798 1/20 0.52
CA3 P07451 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8611481 0.87 MEN1 (0.63) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL1403606 0.84 MEN1 (0.56) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL13715092 0.84 SRC (0.47) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL17144199 0.83 SRC (0.55) MEN1KMT2ASMN1; SMN2L3MBTL1CA1
SCHEMBL907017 0.83 RXFP1 (0.53) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL11297176 0.81 KMT2A (0.67) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL3650502 0.81 POLB (0.49) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL12245467 0.81 KMT2A (0.71) MEN1KMT2ATDP1LMNACYP1A2
SCHEMBL3900754 0.80 ALDH1A1 (0.53) MEN1KMT2ALMNACA1CA2
SCHEMBL23098267 0.80 HSD17B10 (0.56) MEN1KMT2ATDP1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117136307-A Methods, assays and systems for detecting target analytes 索伦托治疗有限公司 2023-11-28 CN claimed
EP-4278183-A1 METHODS, ASSAYS AND SYSTEMS FOR DETECTION OF A TARGET ANALYTE Sorrento Therapeutics, Inc. (US) 2023-11-22 EP claimed
WO-2022155380-A1 METHODS, ASSAYS AND SYSTEMS FOR DETECTION OF A TARGET ANALYTE VIREX HEALTH, INC. (US) 2022-07-21 WO claimed
US-20210292353-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-09-23 US claimed
EP-3829565-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2021-06-09 EP claimed
WO-2020025488-A1 INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE Karlsruher Institut für Technologie (DE) 2020-02-06 WO claimed
US-20170112948-A1 Inorganic-organic hybrid compound Karlsruher Institut für Technologie (DE) 2017-04-27 US claimed
EP-3122756-A1 INORGANIC-ORGANIC HYBRID COMPOUND Karlsruher Institut für Technologie (DE) 2017-02-01 EP claimed
WO-2015144282-A1 INORGANIC-ORGANIC HYBRID COMPOUND Karlsruher Institut für Technologie (DE) 2015-10-01 WO claimed
CN-101395473-A Water-soluble conjugates for electrochemical detection INVILLNIS MEDICINE SWISS CO LT (CH) 2009-03-25 CN claimed
WO-2007123507-A1 WATER-SOLUBLE CONJUGATES FOR ELECTROCHEMICAL DETECTION INVERNESS MEDICAL SWITZERLAND GMBH (CH) 2007-11-01 WO claimed
US-20060205090-A1 Water-soluble conjugates for electrochemical detection OAKVILLE HONG KONG COMPANY LIMITED (HK) 2006-09-14 US claimed
EP-0759171-B1 PARACETAMOL PHOSPHATE FOR IMMUNOASSAYS CAMBRIDGE LIFE SCIENCES (GB) 1998-04-15 EP claimed
EP-0759171-A1 PARACETAMOL PHOSPHATE FOR IMMUNOASSAYS CAMBRIDGE LIFE SCIENCES PLC (GB) 1997-02-26 EP claimed
US-5602277-A Substituted benzene derivatives useful as neuraminidase inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 1997-02-11 US claimed
WO-1996030329-A1 SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS BIOCRYST PHARMACEUTICALS, INCORPORATED (US) 1996-10-03 WO claimed
WO-1995031724-A1 PARACETAMOL PHOSPHATE FOR IMMUNOASSAYS CAMBRIDGE LIFE SCIENCES PLC (GB) 1995-11-23 WO claimed
US-4322410-A P-Acetaminophenyl phosphate salts as analgesics and antipyretics Dugniolle, Jacques (FR) 1982-03-30 US claimed
US-12607589-B2 Methods, assays and systems for detection of a target analyte SORRENTO THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
US-4322410-A P-Acetaminophenyl phosphate salts as analgesics and antipyretics Dugniolle, Jacques (FR) 1982-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170112948-A1 Inorganic-organic hybrid compound SLCO4C1, SLCO2A1, SLCO1A2 MEN1 1681/4885KMT2A 3120/4885TDP1 3934/4885
US-12607589-B2 Methods, assays and systems for detection of a target analyte PRSS3, PRSS2, ZP1 MEN1 3062/4885KMT2A 3740/4885TDP1 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.